Our commercially validated ENHANZE® drug delivery technology, based on our proprietary enzyme rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. When co-formulated with other drugs, ENHANZE® has the potential to reduce treatment burden for patients, including potentially reducing treatment administration from hours-long IV infusions to subcutaneous injections delivered in minutes.
We have expanded our technology platform offering by adding a range of auto-injectors designed for subcutaneous and intramuscular use. With more than 30 years of experience in auto-injector device development and engineering, our internal development team specializes in creating custom designed drug delivery devices that address patient and therapeutic needs.
In addition, we market and commercialize four FDA-approved products featuring our unique and proprietary development and delivery technologies.